Efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications

被引：9

作者：

Borad, M. ^{[1
]}

Javle, M. ^{[2
]}

Shaib, W. L. ^{[3
]}

Mody, K. ^{[4
]}

Bergamo, F. ^{[5
]}

Harris, W. P. ^{[6
]}

Damjanov, N. ^{[7
]}

Macarulla, T. ^{[8
]}

Brandi, G. ^{[9
]}

Masi, G. ^{[10
]}

Busset, M. Droz Dit ^{[11
]}

Boncompagni, A. ^{[12
]}

Dimova-Dobreva, M. ^{[12
]}

Engelhardt, M. ^{[12
]}

Saulay, M. ^{[12
]}

Halfdanarson, T. R. ^{[13
]}

Knox, J. ^{[14
]}

Abou-Alfa, G. K. ^{[15
]}

Personeni, N. ^{[16
]}

Mazzaferro, V. ^{[17
]}

机构：

[1] Mayo Clin Canc Ctr, Dept Oncol, Scottsdale, AZ USA

[2] Univ Texas MD Anderson Canc Ctr, Gastrointestinal Med Oncol, Houston, TX USA

[3] Emory Univ, Hematol & Oncol, Atlanta, GA USA

[4] Mayo Clin, Hematol & Oncol, Jacksonville, FL USA

[5] IOV Ist Oncol Veneto IRCCS, Dipartimento Oncol 1, Padua, Italy

[6] Univ Washington, Med, Med Ctr, Seattle, WA USA

[7] Univ Penn, Abramson Canc Ctr, Hematol & Oncol, Philadelphia, PA USA

[8] Vall Hebron Inst Oncol, Med Oncol, VHIO Cellex Ctr, Barcelona, Spain

[9] Univ Bologna, Med Oncol, IRCCS Azienda Osped, Bologna, Italy

[10] AOU Pisana Stabilimento Santa Chiara, Oncol Med, Pisa, Italy

[11] Fdn IRCCS, Hepatopancreatobiliary & Digest Surg, Ist Nazl Tumori Milano, Milan, Italy

[12] Basilea Pharmaceut Ltd, Dept Dev, Basel, Switzerland

[13] Mayo Clin, Dept Med Oncol, Rochester, NY USA

[14] Princess Margaret Canc Ctr, Oncol Med, Toronto, ON, Canada

[15] Mem Sloan Kettering Evelyn H Lauder Breast Ctr, Dept Med, New York, NY USA

[16] Ist Clin Humanitas, Dept Oncol & Hematol, Rozzano, Italy

[17] Fdn IRCCS, Oncol Med, Ist Nazl Tumori Milano, Milan, Italy

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.087

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

59P

引用

页码：S567 / S568

页数：2

共 50 条

[41] ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations.
Mazzaferro, Vincenzo
El-Rayes, Bassel F.
Cotsoglou, Christian
Harris, William Proctor
Damjanov, Nevena
Masi, Gianluca
Rimassa, Lorenza
Personeni, Nicola
Braiteh, Fadi S.
Zagonel, Vittorina
Papadopoulos, Kyriakos P.
Hall, Terence
Wang, Yunxia
Abbadessa, Giovanni
Schwartz, Brian E.
Kazakin, Julia
Busset, Michele Droz Dit
Shaib, Walid La Bib
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[42] FGFR2 fusion/rearrangement is associated with favorable prognosis and immunoactivation in patients with intrahepatic cholangiocarcinoma
Liu, Shaoqing
Weng, Jialei
Cao, Manqing
Zhou, Qiang
Xu, Min
Xu, Wenxin
Hu, Zhiqiu
Xu, Minghao
Dong, Qiongzhu
Sheng, Xia
Zhou, Chenhao
Ren, Ning
ONCOLOGIST, 2024, 29 (12): : e1734 - e1747
[43] TARGETING FGFR2-FUSIONS WITH ANTIBODY THERAPEUTICS IN INTRAHEPATIC CHOLANGIOCARCINOMA
Chaturantabut, Saireudee
Oliver, Sydney
Federick, Dennie T.
Kim, John
Robinson, Foxy
Sellers, William R.
HEPATOLOGY, 2023, 78 : S2139 - S2139
[44] Detection of Known and Novel FGFR2 Geneomic Alterations in Intrahepatic Cholangiocarcinoma
Pu, Xiaohong
Fu, Yao
Fan, Xiangshan
Chen, Jun
Sun, Beicheng
LABORATORY INVESTIGATION, 2023, 103 (03) : S1405 - S1407
[45] Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial
Makawita, Shalini
Abou-Alfa, Ghassan K.
Roychowdhury, Sameek
Sadeghi, Saeed
Borbath, Ivan
Goyal, Lipika
Cohn, Allen
Lamarca, Angela
Oh, Do-Youn
Macarulla, Teresa
Shroff, Rachna T.
Howland, Michael
Li, Ai
Cho, Terry
Pande, Amit
Javle, Milind
FUTURE ONCOLOGY, 2020, 16 (30) : 2375 - 2384
[46] Clinicopathological nomogram for predicting fibroblast growth factor receptor 2 (FGFR2) gene fusion/rearrangement (F/R) in intrahepatic cholangiocarcinoma (iCCA)
Bensi, M.
Giannarelli, D.
Bagala, C.
Niger, M.
Bergamo, F.
Barone, D.
Rizzato, M. D.
Nichetti, F.
Spring, A.
De Rosa, A.
Beccia, V.
Ricagno, G.
Pircher, C. C.
Ardito, F.
Barbaro, B.
Giuliante, F.
Martinelli, E.
De Braud, F. G. M.
Lonardi, S.
Tortora, G.
Salvatore, L.
ANNALS OF ONCOLOGY, 2023, 34 : S229 - S229
[47] Therapeutic targeting of extracellular FGFR2 activating deletions in intrahepatic cholangiocarcinoma
Cleary, James M.
Raghavan, Srivatsan
Li, Yvonne Y.
Spurr, Liam
Wu, Qibiao
Shi, Lei
Brais, Lauren K.
Odhiambo, Zunelly
Goyal, Lipika
Patel, Anuj K.
Shinagare, Atul B.
Clancy, Thomas E.
Shapiro, Geoffrey
Cerami, Ethan
Sellers, William R.
Hahn, William C.
Cherniack, Andrew D.
Bardeesy, Nabeel
Meyerson, Matthew
Wolpin, Brian M.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[48] Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing
Neumann, Olaf
Burn, Timothy C.
Allgaeuer, Michael
Ball, Markus
Kirchner, Martina
Albrecht, Thomas
Volckmar, Anna-Lena
Beck, Susanne
Endris, Volker
Goldschmid, Hannah
Lehmann, Ulrich
Seker-Cin, Huriye
Uhrig, Sebastian
Roessler, Stephanie
Budczies, Jan
Froehling, Stefan
Longerich, Thomas
Wagner, Alex H.
Vogel, Arndt
Schirmacher, Peter
Stenzinger, Albrecht
Kazdal, Daniel
BRITISH JOURNAL OF CANCER, 2022, 127 (08) : 1540 - 1549
[49] Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing
Olaf Neumann
Timothy C. Burn
Michael Allgäuer
Markus Ball
Martina Kirchner
Thomas Albrecht
Anna-Lena Volckmar
Susanne Beck
Volker Endris
Hannah Goldschmid
Ulrich Lehmann
Huriye Seker-Cin
Sebastian Uhrig
Stephanie Roessler
Jan Budczies
Stefan Fröhling
Thomas Longerich
Alex H. Wagner
Arndt Vogel
Peter Schirmacher
Albrecht Stenzinger
Daniel Kazdal
British Journal of Cancer, 2022, 127 : 1540 - 1549
[50] Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma
Kongpetch, Sarinya
Jusakul, Apinya
Lim, Jing Quan
Ng, Cedric Chuan Young
Chan, Jason Yongsheng
Rajasegaran, Vikneswari
Lim, Tse Hui
Lim, Kiat Hon
Choo, Su Pin
Dima, Simona
Popescu, Irinel
Duda, Dan G.
Kukongviriyapan, Veerapol
Khuntikeo, Narong
Pairojkul, Chawalit
Rozen, Steven G.
Tan, Patrick
Teh, Bin Tean
JCO GLOBAL ONCOLOGY, 2020, 6 : 628 - 638

← 1 2 3 4 5 →